1) Tirzepatide for the treatment of obesity. Weekly subcutaneous Tirzepatide, a dual GLP-1 receptor agonist and glucose-dependent insulinotropic polypeptide (GIP) agonist, led to a mean reduction in weight of 15% with 5 mg doses, 19.5% with 10 mg doses, and 20.9% with 15 mg doses. Jastreboff A, et al. New England Journal of Medicine 2022;387(3):205-216
2) Dulaglutide for pediatric type 2 diabetes. Treatment with dulaglutide was effective in improving glycemic control among youths with type 2 diabetes who were being treated with or without metformin or basal insulin, without an effect on BMI. Arslanian S, et al. New England Journal of Medicine 2022;387(5):433-443.
5) Do not routinely test for vitamin D. Routine testing for vitamin D levels in asymptomatic individuals is not recommended, based on a lack of evidence for benefit. McChesney C, et al. British Medical Journal 2022;378:e070270